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THE EFFECT OF ADVANCED GLYCATION ENDPRODUCT 
ACCUMULATION ON BONE 
MIRANDA J. VAN VLIET 
ABSTRACT 
 Diabetes is associated with increased fracture risk, which leads to increased 
morbidity and eventual mortality with a substantial financial burden.  Type 2 Diabetics 
also have increased fracture risk, despite having the same or higher BMD as non-
diabetics with a low fracture risk. One hypothesis for this is increased modifications 
made to the extra-cellular matrix via non-enzymatic glycation (NEG) that can occur in a 
hyperglycemic environment, such as with diabetes. The accumulation of NEG products, 
known as advanced glycation endproducts (AGEs) can possibly lead to microdamage and 
eventual weakening of the bone itself. We developed a time-response model in order to 
induce a wide range of AGEs in a manner that would sustain the mineral integrity of the 
bone and could be applied to a variety of bone sample types. This was performed on 65 
rat tibias, distributed amongst 8 groups (3,7,10, & 14 days) for both ribose and control. 
Secondly, the protocol was performed on human cortical beam samples cut from 10 
donor tibias with 3,5 and 7 day time points for ribose and control groups. All samples 
were incubated in a 0.6 M ribose solution or 0.0 M ribose control solution. There was a 7, 
4, and 5-fold increase in AGEs at the 7, 10, and 14 day time points respectively over 
controls in the rat tibia study. There was no significant variation in cortical porosity, 
however TTMD was significantly less dense in the 14-day ribose treated groups. There 
was a trend toward higher AGEs with time in the human cortical beam specimens, but no 
  vii 
significant increase. The AGEs values in the human cortical beam specimens were much 
lower than expected based on previous trials and reports in the literature.  We were able 
to establish a time-response model for AGE accumulation in bone. However, the effects 
of AGEs on bone material properties remains inconclusive.  
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 1 
INTRODUCTION 
 
 Osteoporosis and Type 2 diabetes mellitus are both widespread, chronic diseases 
associated with aging. The resulting complications, such as fragility fractures with 
osteoporosis and renal and vascular complications with diabetes, lead to increased 
morbidity and eventual mortality with a substantial financial burden [1] [2]. Diabetes 
itself has been associated with an increased risk of fracture. Type 1 diabetics have a much 
higher risk of fracture; a 2007 meta-analysis reported their risk at 6.3 fold greater than 
nondiabetics [3] and a recent epidemiological study from Scotland reported a 3.5 fold 
greater risk [4]. Comparatively low, type 2 diabetics have 1.4-1.7 increased fracture risk 
compared to nondiabetics [1]. This is intriguing, however, as type 2 diabetics often have 
the same or higher BMD as non-diabetics with a low fracture risk [1]. The increased 
fracture risk seen in diabetic patients seems likely to be an issue of bone “quality” rather 
than a reduction in bone mass [1] [5]. Bone quality refers to the bone tissue’s properties, 
excluding BMD, that affect its ability to resist fracture [6]. This includes bone 
microarchitecture—the structure and geometry of cortical and trabecular bone—and 
modifications to the extra cellular matrix [2].  For example, a leading hypothesis for the 
increased risk of fracture in type 2 diabetics is that there is increased cortical porosity. 
Diabetes also has complications that increase the risk of falls that could lead to increased 
fracture risk, though when this is adjusted for in models the fracture risk still remains.  
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 Another bone quality factor that contributes to this increased risk are 
modifications made to the extra cellular matrix via non-enzymatic glycation, particularly 
changes made to collagen. Collagen is the most-abundant protein family in the body, and 
its elasticity plays an important role in bone’s ability to resist fracture by keeping the 
bone from becoming too brittle and by being loaded and unloaded without deformation 
[7].  In a hyperglycemic environment or with aging, sugars can spontaneously react with 
amino residues on the collagen chains and form advanced glycation endproducts (AGEs), 
either as adducts on a single protein strand or by forming non-enzymatic crosslinks 
amongst neighboring proteins [7] [2] [5]. Also known as the Maillard reaction, AGEs are 
formed when a reducing sugar, such as glucose and its intermediates, interact with lysine 
or argine residues of protein to form a Schiff base which is successively rearranged to 
form an Amadori product, a reversible intermediate [8]. From there, several more and 
varied rearrangements occur and results in biochemically diverse, irreversible AGEs. 
These unregulated post-translational changes to collagen can deter its function by making 
it less elastic. It also makes it less likely to be recognized by collegenase for turnover [7]. 
Collagen is a long-lived protein anyway, with an up to two year half-life in bone [7], 
allowing ample time for AGE accumulation and the potential for resulting microdamage 
and eventual weakening the bone itself [8] [2].  
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Figure 1: A 7-day trial in rat humeri did not respond in a dose-dependent manner. 
(A) The AGE values changed from concentration to concentration with no discernable 
pattern. (B) The BMD was significantly lower in the 0.4 and 0.6 group compared to the 
control group. * indicates a p-value <0.05 between ribose and control groups. 
 
In a background study, we investigated the hypothesis that the accumulation of advanced 
glycation endproducts (AGEs) result in altered material properties directly with 
accumulation levels, the goal was to develop an in vitro protocol that would result in 
linear pattern of increase of AGEs in bone. Starting with an established 7-day protocol of 
a 0.6 M ribose [9], the initial approach was to change the concentration of ribose to create 
different “doses” of AGEs in the rat humeri. The chosen concentrations were 0.2, 0.4, 0.6 
and 0.8 M ribose vs. a control solution of 0.0 M ribose. Rather than getting a range of 
AGE values that increased positively with ribose concentration, the results were 
nonsensical. The control group AGE values were low, however, the 0.4 M ribose group 
had greater AGE values than the 0.8 M group. This was particularly strange because it 
did not resemble a dose plateau, as it would if the ribose or available amino residues 
became limited. Furthermore, bone mineral density (BMD) as assessed by DXA was 
lower in the 0.4 and 0.8 M ribose groups compared to control. It cannot be definitively 
stated that this is loss over time due to the incubation, because baseline BMD 
g/
cm
2
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measurements were not performed. Yet, the fact that the BMD differed would make it 
impossible to determine if changes in material properties were due to increased AGEs 
affecting the extra-cellular matrix or if it were due to lower mineral density. This 
experiment was also plagued by wildly fluctuating pH levels, which aroused suspicion 
that the acidic environment kept the reaction from occurring properly and demineralized 
the bones [10]. 
Using this first pilot as a learning experience, the focus was switched to 
developing a time-response model in order to induce a wide range of AGEs in a manner 
that would (a) not degrade the mineral integrity of the bone, (b) could be applied to a 
variety of bone types, and (c) measure the effect of AGEs on the material properties of 
the bone via reference point indentation.  
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METHODS  
 
 For all the pilot experiments performed in rat specimens, the long bones were 
harvested from 5-month old female Fischer rats, generously donated by the Porter 
laboratory. Bones harvested include the right and left humerus and radius, right femur, 
and the right and left tibias. For the tibias, initial analysis showed no difference in 
microarchitecture between the right and left sides; therefore, they were pooled together 
for the remainder of the analysis. The humeri were used for the dose-response study, 
discussed in the introduction. 65 tibias were collected and used for the 14-day time 
response study that is the main focus of this thesis. The tibias were evenly distributed 
amongst 8 groups on baseline BMD and geometry. The groups were: 3, 7, 10 and 14 days 
control incubated, and 3, 7, 10 and 14 days ribose incubated (Fig. 1A).  
 Human cortical bone specimens were cut from 10 donor tibias (see Table 1). All 
120 2x4x30 mm beams used in the glycation incubation experiment were cut from the 
medial side of the tibial diaphysis (Fig. B1). The beams were treated individually and 
evenly distributed to groups based on baseline BMD and RPI properties. The study 
included three separate time points: 3, 5 and 7 days, with a ribose and control group at 
each time point.  
 Rat and human bone specimens were incubated in either a 0.6 M ribose solution 
or a control solution with no added ribose [Fischer]. The solutions were composed 
primarily of Hank’s Buffer [Sigma Aldrich]. The rat tibias were numbered with water-
safe tags and the human beams were placed in labeled, mesh biopsy bags that allowed for 
submersion of the bone specimen within the solution. Each solution was contained in a 
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heat-safe glass container large enough to contain all the specimens of a given group, and 
incubated in a water-bath at 37 degrees C for up to two weeks. They were only removed 
for pH checks, which occurred between one and five times daily to ensure that the 
solutions remained at physiological pH between 7.2 and 7.6. Adjustments to pH were 
made using HCL or NaOH as necessary. There were no other additions or changes made 
to the solutions throughout the course of the experiments. Once removed from the 
incubation solution, the specimens were wrapped in saline soaked gauze and stored at -20 
C until further testing.  
   
   
 
 
 
 
 
 
Assessment of whole bone or cortical beam BMD was performed before and after 
incubation using peripheral DXA (PIXImusII, GE Lunar Corp), as previously described 
[11].  
 Bone microarchitecture of the rat tibial midshaft and cortical beam was assessed 
with high-resolution µct (µCT40, Scanco Medical), as previously described [11]. Scans 
were acquired using a 12 µm3 isotropic voxel size, 70 kvp, 114 mA and 200-msec 
Table 1: Demographic information of donor tibias. 
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integration time and were subjected to Gaussian filtration and segmentation. For both 
studies, transverse µCT slices spanning 1200 µm were obtained. Outcome variables 
obtained included cortical thickness, bone area, bone area/total area, cortical porosity, 
total tissue mineral density, pmoi, Imax and Imin. Terminology and units followed the 
recommendations of the American Society for Bone and Mineral Research [14].  
 Cortical bone indentation properties of the beams were measured in the cortical 
bone before and after incubation via reference point indentation (Biodent, Active Life 
Scientific). This system was equipped with a 90 degree conical 2.5 µm radius test probe. 
Indentation was performed at 10 N for 10 cycles [12]. Three indentations of 10 cycles 
each were taken at the proximal end of the beam prior to incubation and from the distal 
end following incubation.  The indentations were spaced a minimum of 500 µm apart. 
Outcome variables include: 1st cycle indentation distance, 1st cycle unloading slope, 1st 
cycle creep indentation distance, average creep indentation distance, total indentation 
distance, average unloading slope, average loading slope, and energy dissipation.  
To prepare for AGE assessment a small amount of bone was cut from the tibial 
diaphysis or beam midsection. In a small subset of beams, another piece was later 
removed from the distal end of the beam. The bone samples were then defatted with 
isopropyl ether, lyophilized overnight, and then hydrolyzed in 6 N HCL at 110 degrees C 
for 20 hours at a ratio of 10 µL for every mg dry weight of bone. The resulting 
hydrosolates were then wrapped in foil to block light and stored at –80 degrees C until 
use in AGE assay [11] . 
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 A flourometric assay was used to quantify AGEs (11) using a microplate reader 
(SynergyMX, Biotek). Collagen content was calculated based on the hydroxyproline 
content. Total fluorescent AGEs were quantified as nanogram quinine/ mg collagen.  
 Standard descriptive statistics were calculated for all outcomes and data checked 
for normality. The effect of treatment and time in incubation were tested using a 2-way 
ANOVA or Kruskal-Wallis for non-normal variables. All tests were two-tailed, with 
significance set at α = 0.05 unless otherwise noted. 
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RESULTS 
 
 
14-day incubation in rat tibias 
pH fluctuations differed between the experimental and the control group, with the 
ribosylated group experiencing greater changes in pH levels. The average change in pH 
value between checks for the control group was 0.008 units whereas the change for the 
ribose group was 0.47 units. The control group experienced a pH drop early in the 
incubation, but then maintained a consistent pH within range for the remaining 
incubation time (Fig. 2).  
For any time point during the incubation, the control treated tibias did not have a 
greater amount of AGEs than any other control group (mean day 3: 124 ±95, day 7: 93 
±46, day 10: 144 ±112, day 14: 125 ±83 ng quinine/mg collagen). The amount of AGEs 
in the ribose treated tibias increased from day 3 to day 7, but they did not increase 
anymore for the duration of the incubation (Figure 2). The average amount of AGEs for 
day 3-ribose group was 249 ±125 ng quinine/mg collagen, whereas the day 7, 10 and 14 
day-ribose groups were 719 ±150, 770 ±270, 760 ±142 ng quinine/mg collagen 
respectively (Fig. 2). Compared to their control counterparts, the ribose treated bones had 
significantly greater amount of AGEs at every time point, except for the 3 day time point. 
This represents an approximate 7, 4, and 5 fold increase in ribosylation over the control 
counterparts at each of the significant time points. Overall, both time (p =0.0002) and 
treatment (p <0.0001) had an impact on the ribosylation of the tibias, with a resulting 
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interaction of p=0.015 (Figure 2). 
 
Figure 2: pH fluctuations and AGE accumulation during 14-day time-response trial 
in rat tibias. (A) The pH of the control solution was stable during the incubation, falling 
out of range (between 7.2 & 7.6) once in the beginning of the incubation. pH fluctuated 
dramatically in the ribose solution during the first week of the experiment, but became 
more stable as the incubation continued. (B) In the control incubated specimens, the AGE 
values did not change over the course of the experiment. In the ribose incubated 
specimens, the AGE values increased between the 3 and 7 day time point, but did not 
increase with time after that. AGE values were greater in all the ribose incubated 
specimens compared to the control incubated specimens at every time point, except for 
the day 3. * indicates a p-value <0.05 between ribose and control groups. The black bar 
indicates a difference over time within the ribose group, compared to the day 3 time 
point, p-value <0.05.  
 
There were some small and expected variations between the groups for total area, PMOI, 
Imax and Imin. This variation in size is not unusual considering we used bones from 
several different animals and did not base the groups on these variables as they are 
unlikely to impact the outcome of the experiment. Likewise, there was no significant 
variation between groups for % BA/TA (Table 2). More importantly, there was no 
significant variation in TTMD (mg HA/cm3) or cortical porosity (%) between the 3, 7, 10 
or 14 day control groups. There was no variation for the ribose treated bones regarding 
Ct. Porosity (%), however for TTMD, the day 14-ribose was significantly less dense 
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compared to both the day 3-ribose group (1028 ±13 vs 1053 ±17, p =0.0024) and the day 
14-control group (1028 ±13 vs 1047 ±8, p=0.0052). Overall, neither time nor treatment 
had an impact on ct. porosity (p >0.1 for both), however, time did have a significant 
impact on TTMD (p = 0.03), though treatment remained insignificant (p =0.6) (Fig.3). 
Figure 3: In vitro incubation of rat tibias in a 0.6 M ribose solution for 14-days did 
not affect Ct. Porosity (%), but did affect TTMD as assessed by µCT. (A) Ct. 
Porosity (%) did not vary over time within either the control or ribose-treated groups. 
There were no significant differences between controls and ribose-treated groups at any 
time point. (B) TTMD was significantly less for the day 14-ribose group compared to the 
day 3-ribose and day 14-control group, suggesting an effect of both treatment and time 
beyond the 10 day mark. * indicates a p-value <0.05 between ribose and control groups. 
The black bar indicates a difference over time within the ribose group, compared to the 
day 3 time point, p-value <0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Summary of µCT outcomes. 
(mg HA/cm3 ) 
(M
g 
H
A
/c
m
3
) 
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7-day human cortical beam incubation 
In the human beam incubation trial, the pH of the incubation solutions remained 
stable throughout the experiment. There was no change over time within the control 
specimens for any time point for AGE values. While the value of AGEs between the 
control group and the ribose group were not significantly different from each other at the 
three day time point, there was a significant difference between control and ribosylated at 
the 5 and 7-day time points. Overall, there was a significant increase in AGEs with 
incubation (p=0.0002). While not significant, there was a trend towards an increase with 
time. It should be noted, however, that the AGE values were much lower than expected 
based on previous trials and published literature. Considering this, I quantified the AGEs 
again, this time using a subset of 20 bone pieces cut from the distal end of the beam to 
see if AGEs varied along the length of the beam, based on the hypothesis that the end of 
the beam would have increased surface area and therefore increased AGEs. In that trial, 
the pattern for differences between groups and time points remained the same as it was 
for the midbeam AGE levels, though there was a slight but insignificant increase in 
AGEs.    
 There was no variation in the baseline BMD of the bones at the day 3,5, or 7 time 
point in either the ribose or control groups. After the 7 day incubation, there was still no 
variation in BMD at the 3,5, or 7 day time point, though there was an overall significant 
increase in BMD amongst the bones from baseline. However, this less than 2% increase 
is likely measurement error.  
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 TTMD and Ct. porosity did not vary between the control or ribose groups at the 
3,5, or 7 day time point. TTMD and ct. porosity did not vary over time with either the 
ribose or control groups.  
 There was no variation between ribose and control beams at any of the three time 
points for 1st cycle indentation distance, 1st creep indentation distance, total indentation 
distance, or average creep indentation distance. 1st cycle unloading slope was also not 
significant. There were small but significant variations in the average loading and 
unloading slopes. Average unloading slope was higher in the ribosylated bones at 3, 5 
and 7 day time points (p-treatment = 0.01). In the ribosylated beams, average unloading 
slope increased with time spent in incubation (p = 0.05). This suggests that there is an 
interplay between treatment and time, with a p-interaction of 0.003. For average loading 
slope, the pattern was the same as with average unloading slope only more significant (p-
treatment = 0.0002, p-time = 0.0001, p-interaction = 0.0001).  
 
. 
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DISCUSSION 
 
 There are many reasons the initial pilot in the rat humeri failed. The obvious 
reason is that the experiment was beleaguered by fluctuating pH that kept falling out of 
the physiological range of 7.2 and 7.6. One reason this might have happened is because 
during glycation an acidic intermediary product is formed that could create more 
instability in the ribose solutions compared to the control solutions. While this would also 
occur in the 0.6 M solution, the buffers were optimized for that concentration. Changing 
the concentration of the ribose without changing the amounts of the other components 
would alter their concentration as well, possibly resulting in a less optimal environment 
for the incubation to occur. Furthermore, the bones were all kept in individual tubes, 
making pH checks laborious and impractical to do more than once a day. It is unknown 
whether other researchers had issues with demineralization since it is not reported in the 
literature. Following this failure, it seemed a more direct approach was to abandon the 
dose-response model and focus on a time-response model that would maintain the 
established and optimized 0.6 M. Another major change was to keep all the specimens in 
a large container, and pull them out at their assigned time point. Thirdly, pH checks were 
increased to at least twice a day until pH stability was established.  
The ribose experienced considerable pH fluctuations throughout the rat tibia trial, 
though these became less dramatic as time went on. This fluctuation was unanticipated 
for this experiment; since making the adjustments to the experimental protocol, this 
fluctuation was not seen in pilot experiments. This variation is likely due to the decreased 
ratio of buffer volume to sample volume, as the rat tibias were inherently larger and the 
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number of specimens greater than in prior pilot experiments, while the volume of the 
solution was not changed as it was sufficient to keep the bones submerged. This theory is 
somewhat validated by decreased fluctuation in the latter part of the experiment as 
samples were removed at the 3,7, and 10 day time points resulting in an increased buffer 
to sample volume ratio.  To combat the problem of pH dropping out of range, the 
frequency of pH checks was increased to approximately every three hours.  This 
minimized the time that the solutions were out of range, which had the dual effect of 
keeping the mineral integrity of the bones intact and maximizing the effectiveness of the 
incubation protocol.  For the human cortical beam trial, the specimens were smaller than 
rat tibias and the volume of the incubation solution was increased so that there was a 
greater ratio of incubation solution to bone surface area. The pH remained steady 
throughout the experiment, suggesting that the ratio is partially effective at keeping the 
solution stable. 
The drastic increase in AGE accumulation between 3 and 7 days in the rat tibias 
followed by a lack of change between 7 and 10 days suggests that there is saturation point 
for non-enzymatic glycation. It seems unlikely that the plateau occurred due to substrate 
exhaustion as a 0.6 M concentration guarantees ribose in excess for the chemical 
reaction. It seems more likely that there was a finite amount of arginine and lysine 
residues available along the surface area of the bone for the reaction to take place with. 
However, the original protocol that this experiment was based on called for a 7-day 
incubation period. It is possible that components of the solution meant to keep the bone 
from degradation, such as protease inhibitors, were depleted in the first week of the 
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experiment allowing for the some collagen and other protein degradation to occur. This 
theory is supported by the fact that TTMD was significantly lower in the 14 day ribose 
group. As expected, ex-vivo non-enzymatic glycation did not have an effect on the 
microarchitecture of the bone. Yet, the decrease in the day14-ribose group is suggestive 
mineral degradation due to issues with pH fluctuation and perhaps the depletion of 
protease inhibitors in the incubation solution. Based on the bone degradation seen in the 
14-day time point of the rat tibia study that time point was dropped from the human trial 
and a 5-day time point was added. While there was no degradation seen in the human 
cortical beams, the values were lower suggesting that perhaps the human beams needed 
to go out to 14 days and perhaps would not have suffered the same degradation as the rat 
tibias did.  
The values of the AGEs were much lower than expected in the human beam trial. 
One hypothesis for this phenomenon is that the beams have less surface area than an 
irregularly shaped rat tibia. Less surface area is equal to less room for the reaction to take 
place. This is supported by the fact that that AGEs were higher at the distal end of the 
beam than the midbeam, where the distal beam has more exposed edges. However, the 
values at the distal end of the beam were still lower than previous trials in rat bones and 
in the published literature. To the best of my knowledge, this is the first time that this in 
vitro incubation has been measured in human cortical bone only, as many past studies 
have been done in human cancellous bone cores or bovine plugs. The material properties 
of the two types of bone and between species might mean these beams require a longer 
incubation time as the solution might diffuse slower through the denser material. 
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Furthermore, cancellous bone with its numerous trabeculae that create its sponge-like 
texture increases the surface area over cortical bone, which helps explain the difference in 
AGE values. It would surely be worth the time to repeat this protocol with a single 14-
day time point to see if that increases the AGE values to expected range. I do not believe 
these low AGE values are erroneous, because they do fall at the low end of the reported 
range.  
 
Figure 4: 7-day cortical beam incubation trial results. (A and B) BMD did not vary 
between ribose and control groups at baseline and after the incubation. Neither did it vary 
over time. (C) Ct. Porosity (%). (D) AGE values were greater on in the ribose-treated 
(n=120) at the midbeam at the 5 and 7-day timepoint. AGE values were greater in the 
ribose-treated beams at the distal end at the 3, 5, and 7-day timepoint beams (n=20). 
 
A limitation of the beam study, is that the porosity of the beams was much higher 
than expected for cortical bone. This is likely due to the fact that some of the specimens 
g/
cm
2
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were cut and polished to the designated dimensions, but trabeculae remained. Even after 
excluding specimens that obviously included trabecular bone (as identified in the µCT 
scan images), the average cortical porosity remained at approximately 15% and ranged as 
high as 30%. While unusual, the beams were cut from cadaveric donor tibias, some of 
whom were reported to have osteoporosis and/or were wheel-chair/bed bound, which 
helps explain some of the large variation in cortical porosity. It is worth noting that 
another set of beams were cut from the lateral sides of the same donor tibias and used in a 
different experiment. These beams did not have the same high cortical porosity as the 
medial beams used for this study. This suggests that porosity and perhaps cortical 
thickness varies by location in the human tibia.  
 
 
 
 
 
 
The overall results of reference point indentation were disappointing, but not 
unexpected based on previous studies in the laboratory. While some have found 
differences in the material properties of diabetic and non-diabetic bone [13], these were 
done in tissue exposed to chronic hyperglycemia during life and not an in vitro 
experiment. Furthermore, as mentioned earlier, the accumulation of AGEs was very small 
in the beams, further dampening any effect the incubation might have had on the material 
Table 3: Summary of Reference-Point Indentation outcomes in the human beam trial. 
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properties of the bone. A longer 14-day incubation might help overcome these. The 
results of the average loading and unloading slope does suggest increase stiffness 
amongst the beams. This makes intuitive sense, where the non-enzymatic glycation 
creates crosslinks that stiffen the collagen of the extra-cellular matrix.  
 
Figure 5: Average loading slope and unloading slope were lower in the ribose-treated 
beams. (A & B) There was no difference in TID or IDI between either the ribose or control 
group at any time point. (C & D) Avg. LS and Avg. US were lower in the ribose-treated 
beams at the 3, 5, and 7-day time point. 
 
 In conclusion, we were able to establish a time-response protocol for accumulating 
AGEs in bone after life. We were able to do this without degrading the mineral integrity of 
the bone. However, the effect of AGEs on bone material properties remains inconclusive.  
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APPENDIX A 
 
                                                      
 
 
Figure A1: A 14-day in vitro ribosylation in rat tibias. 65 tibias were distributed 
evenly amongst groups based on BMD into eight groups: 3, 7, 10, and 14-day ribose and 
control groups.
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APPENDIX B 
 
                                         
 
Figure B1: Location and distribution of human cortical beams. (A) Approximately 12 
beams from each donor tibia were cut from 4 sections (S1-S4) along the length of the 
medial side of the tibial diaphysis from 10 donor tibias. (B) Based on baseline BMD and 
RPI variables, the beams were evenly distributed into six groups: 3, 5, and 7-day ribose 
and control groups. 
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